Ophthalmology
Boji Pharmaceuticals is deeply committed to advancing innovative ophthalmic therapies, focusing on conditions such as dry eye syndrome, NAION, and neurotrophic keratitis, and dedicated to driving breakthroughs in the treatment of eye diseases.
INTRODUCTION
In the field of ophthalmic disease research and services, Boji Pharmaceuticals has demonstrated exceptional expertise, focusing on in-depth exploration of treatments for conditions such as dry eye syndrome, neurotrophic keratitis, non-arteritic anterior ischemic optic neuropathy (NAION), and allergic conjunctivitis.
Our team actively participates in clinical trials for these conditions, aiming to offer new hope through the integration of traditional and cutting-edge therapies, including gene therapy and stem cell therapy. Whether enhancing the efficacy of existing treatments or developing novel approaches, Boji Pharmaceuticals is dedicated to alleviating patient suffering while protecting and improving their visual health. We relentlessly pursue scientific breakthroughs to identify optimal treatment strategies for complex ophthalmic disorders.
Clinical Research Project Experience
- Dry eye syndrome
- Neurotrophic Keratitis
- Non-arteritic anterior ischemic optic neuropathy
- Conjunctivitis (Allergic Conjunctivitis)
PROJECT EXPERIENCE
Tianshili Compound Danshen Droplet Pills Successfully Approved for New Indication of Diabetic Retinopathy
In October 2021, the indication for Tianshili Compound Danshen Droplet Pills in treating Stage I (mild) and Stage II (moderate) non-proliferative diabetic retinopathy caused by type 2 diabetes was officially approved, offering a new treatment option for patients with diabetic retinopathy. Leveraging its extensive R&D expertise in traditional Chinese medicine and professional team, Boji Pharmaceutical provided scientific and rigorous management services for the clinical trials of Tianshi Li Compound Danshen Droplet Pills' new DR indication project, ensuring the trials' smooth progress.
